CiteFacts · FDA Drug Shortages · FDA source
FDA shortage status: Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection
FDA source answer
FDA currently lists this ingredient in shortage.
FDA source statuses: Current. First FDA posting: 2018-02-20. Latest FDA row update: 2026-09-22.
FDA lists 20 package records, with companies: Fresenius Kabi USA, LLC, Hospira, Inc., Hospira, Inc., a Pfizer Company. Package NDCs: 0409-1746-10, 0409-1746-30, 0409-1749-10, 0409-1749-29, 0409-1752-50, 0409-1755-50, 0409-9042-01, 0409-9042-17, 0409-9043-01, 0409-9045-01, 0409-9045-17, 0409-9046-01, 63323-460-37, 63323-461-57, 63323-462-17, 63323-462-31, 63323-462-37, 63323-463-57, 63323-468-17, 63323-468-37.
FDA shortage reason: Delay in shipping of the drug; Other
This is nationwide FDA status, not local pharmacy inventory. CiteFacts does not provide medical, treatment, substitution, or dosing advice.
FDA package and manufacturer records
| Company | Package NDC | Presentation | FDA availability field | FDA update |
|---|---|---|---|---|
| Fresenius Kabi USA, LLC | 63323-461-57 | Sensorcaine, Injection, 2.5 mg/1 mL; .005 mg/1 mL (NDC 63323-461-57) | Available | 2026-09-15 |
| Fresenius Kabi USA, LLC | 63323-468-17 | Sensorcaine, Injection, 2.5 mg/1 mL; .005 mg/1 mL (NDC 63323-468-17) | Available | 2026-09-15 |
| Fresenius Kabi USA, LLC | 63323-468-37 | Sensorcaine, Injection, 2.5 mg/1 mL; .005 mg/1 mL (NDC 63323-468-37) | Available | 2026-09-15 |
| Fresenius Kabi USA, LLC | 63323-462-17 | Sensorcaine, Injection, 5 mg/1 mL; .005 mg/1 mL (NDC 63323-462-17) | Available | 2026-09-15 |
| Fresenius Kabi USA, LLC | 63323-462-31 | Sensorcaine, Injection, 5 mg/1 mL; .005 mg/1 mL (NDC 63323-462-31) | Unavailable | 2026-09-15 |
| Fresenius Kabi USA, LLC | 63323-462-37 | Sensorcaine, Injection, 5 mg/1 mL; .005 mg/1 mL (NDC 63323-462-37) | Available | 2026-09-15 |
| Fresenius Kabi USA, LLC | 63323-463-57 | Sensorcaine, Injection, 5 mg/1 mL; .005 mg/1 mL (NDC 63323-463-57) | Available | 2026-09-15 |
| Fresenius Kabi USA, LLC | 63323-460-37 | Sensorcaine, Injection, 7.5 mg/1 mL; .005 mg/1 mL (NDC 63323-460-37) | Available | 2026-09-15 |
| Hospira, Inc., a Pfizer Company | 0409-9042-01 | Bupivacaine Hydrochloride And Epinephrine, Injection, 25 mg/10 mL (2.5 mg/mL) (NDC 0409-9042-01) | Unavailable | 2026-09-22 |
| Hospira, Inc., a Pfizer Company | 0409-9046-01 | Bupivacaine Hydrochloride And Epinephrine, Injection, 250 mg/50 mL (5 mg/mL) (NDC 0409-9046-01) | Unavailable | 2026-09-22 |
| Hospira, Inc., a Pfizer Company | 0409-9045-01 | Bupivacaine Hydrochloride And Epinephrine, Injection, 50 mg/10 mL (5 mg/mL) (NDC 0409-9045-01) | Unavailable | 2026-09-22 |
| Hospira, Inc., a Pfizer Company | 0409-9042-17 | Bupivacaine Hydrochloride And Epinephrine, Injection, 75 mg/30 mL (2.5 mg/mL) (NDC 0409-9042-17) | Unavailable | 2026-09-22 |
| Hospira, Inc., a Pfizer Company | 0409-9043-01 | Bupivacaine Hydrochloride and Epinephrine, Injection, 125 mg/50 mL (2.5 mg/mL) (NDC 0409-9043-01) | Unavailable | 2026-09-22 |
| Hospira, Inc., a Pfizer Company | 0409-9045-17 | Bupivacaine Hydrochloride and Epinephrine, Injection, 150 mg/30 mL (5 mg/mL) (NDC 0409-9045-17) | Unavailable | 2026-09-22 |
| Hospira, Inc., a Pfizer Company | 0409-1752-50 | Marcaine With Epinephrine, Injection, Marcaine with Epinephrine 1:200,000 as the bitartrate 125 mg/50 mL (2.5 mg/mL 1:200,000) (NDC 0409-1752-50) | Available | 2026-09-22 |
| Hospira, Inc., a Pfizer Company | 0409-1749-29 | Marcaine With Epinephrine, Injection, Marcaine with Epinephrine 1:200,000 as the bitartrate 150 mg/30 mL (5 mg/mL 1:200,000) (NDC 0409-1749-29) | Available | 2026-09-22 |
| Hospira, Inc., a Pfizer Company | 0409-1746-10 | Marcaine With Epinephrine, Injection, Marcaine with Epinephrine 1:200,000 as the bitartrate 25 mg/10 mL (2.5 mg/mL 1:200,000) (NDC 0409-1746-10) | Available | 2026-09-22 |
| Hospira, Inc., a Pfizer Company | 0409-1755-50 | Marcaine With Epinephrine, Injection, Marcaine with Epinephrine 1:200,000 as the bitartrate 250 mg/50 mL (5 mg/mL 1:200,000) (NDC 0409-1755-50) | Available | 2026-09-22 |
| Hospira, Inc., a Pfizer Company | 0409-1749-10 | Marcaine With Epinephrine, Injection, Marcaine with Epinephrine 1:200,000 as the bitartrate 50 mg/10 mL (5 mg/mL 1:200,000) (NDC 0409-1749-10) | Available | 2026-09-22 |
| Hospira, Inc., a Pfizer Company | 0409-1746-30 | Marcaine With Epinephrine, Injection, Marcaine with Epinephrine 1:200,000 as the bitartrate 75 mg/30 mL (2.5 mg/mL 1:200,000) (NDC 0409-1746-30) | Available | 2026-09-22 |
Source facts
Grouped generic ingredient: Bupivacaine Hydrochloride, Epinephrine Bitartrate Injection · 20 package records
Therapeutic categories: Anesthesia
Dosage forms: Injection
Routes: EPIDURAL, INFILTRATION, INTRACAUDAL, PERINEURAL, RETROBULBAR
Open FDA source data · JSON · Markdown
FDA is authoritative. Source retrieved 2026-10-06T18:55:41+00:00. Derived grouping is documented in this record's derivations.